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The epidermal growth factor receptor (EGFR or ErbB-1) is a
170 kDa cell surface glycoprotein consisting of a single poly-
peptide chain of 1186 amino acid residues. EGFR binds 6 ligands:
EGF, TGF-α , amphiregulin, heparin-binding EGF-like growth
factor, epiregulin and betacellulin and plays an important role in
the regulation of normal cell growth, proliferation and differentia-
tion (Prigent and Lemoine, 1992). 
In a large number of tumours the EGFR status is altered due to
overexpression, amplification and/or mutations in the EGFR gene.
A significant fraction of amplified EGFR genes are rearranged to
specifically eliminate a DNA fragment containing exons 2–7 of
the gene resulting in an in-frame deletion of 801 base pairs of the
extracellular domain encoding sequence. This rearrangement is
designated as the type III EGFR mutation (EGFRvIII, ∆ EGFR,
de2-7 EGFR) and is the most common mutation in the EGFR
gene. The EGFRvIII has been detected in 16% of non-small-cell
lung cancer (NSCLC), 57% of high-grade glial tumours, 86% of
low-grade gliomas, 66% of paediatric gliomas, 86% of medul-
loblastomas, 78% of breast carcinomas, and 73% of ovarian carci-
nomas (Garcia et al, 1993; Moscatello et al, 1995). In prostate
cancer expression of EGFRvIII appears to increase in a correlated
manner with the gradual transformation of the tissues to the malig-
nant phenotype (Olapade-Olaopa et al, 2000). This high preva-
lence in a wide variety of human tumours suggests that it is
positively selected during the process of tumorigenesis due to
enhancement of the tumour-inducing properties of the EGFR.
Several studies support this hypothesis and strongly indicate a
correlation between the expression of EGFRvIII and an enhanced
tumorigenicity of tumour cells both in vitro and in vivo
(Nishikawa et al, 1994; Batra et al, 1995; Nagane et al, 1996,
1998; Sugawa et al, 1998). Although EGFRvIII is not able to bind
EGF or any of the other EGFR ligands, it is constitutively phos-
phorylated and able to activate downstream signalling cascades.
However, the EGFRvIII seems to utilize a different downstream
signalling network as compared to the ligand-activated EGFR.
The Ras/Raf/ERK pathway appears to be down-regulated by
EGFRvIII, while a pathway composed of phosphatidyl inositol 3
kinase (P13K), and c-Jun N-terminal Kinase (JNK) is constitu-
tively active (Antonyak et al, 1998; Moscatello et al, 1998). This
difference in signalling between EGFRvIII and EGFR may, at
least partly, explain the increased tumorgenicity of EGFRvIII-
expressing cells. 
Very little is known regarding genes whose expression is regu-
lated by EGFRvIII and its downstream-signalling cascade. For the
first time, we set out to identify EGFRvIII-regulated genes.
Affymetrix’ oligonucleotide array Hu6800set, containing probes
for more than 6800 human genes, was used to assay for changes in
mRNA expression between an EGFRvIII transfected human
small-cell lung cancer cell line, GLC3-EGFRvIII, and a vector
control cell line. Amongst the 6800 genes analysed, we found 225
whose expression was altered by at least a factor of 2. These
included genes encoding adhesion molecules, transcription
factors, and signal-modulating molecules. Northern blot and
Western blot analyses were used to confirm selected results. 
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Summary Previous studies have shown a correlation between expression of the EGF receptor type III mutation (EGFRvIII) and a more
malignant phenotype of various cancers including: non-small-cell lung cancer, glioblastoma multiforme, prostate cancer and breast cancer.
Thus, a detailed molecular genetic understanding of how the EGFRvIII contributes to the malignant phenotype is of major importance for
future therapy. The GeneChip Hu6800Set developed by Affymetrix was used to identify changes in gene expression caused by the
expression of EGFRvIII. The cell line selected for the study was an EGF receptor negative small-cell-lung cancer cell line, GLC3, stably
transfected with the EGFRvIII gene in a Tet-On system. By comparison of mRNA levels in EGFRvIII-GLC3 with those of Tet-On-GLC3, it was
found that the levels of mRNAs encoding several transcription factors (ATF-3, JunD, and c-Myb), cell adhesion molecules (CD36, CD24),
signal transduction related molecules (MKP-1) and other molecules related to cancer (CD98, thymosin beta-10) were altered in the EGFRvIII
transfected cell line. Northern hybridisations and Western blot analyses were used to verify selected results. The results indicate that
expression of EGFRvIII alters expression of genes involved in the control of cell growth, survival and motility. © 2001 Cancer Research
Campaign http://www.bjcancer.com
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MATERIALS AND METHODS 
Materials 
Antibodies to MKP-1 and CD98 were obtained from Santa-Cruz
Biotechnology (Santa-Cruz, CA, USA). Precast SDS-PAGE gels
were from Invitrogen (The Nederlands). Platinum Taq polymerase
was from Life Technologies (Scotland). All chemicals were
purchased from Sigma-Aldrich (Denmark) unless otherwise stated. 
Cell culture and treatment 
The EGFRvIII-expressing human small-cell lung cancer cell lines
has been described by Damstrup et al and was generated by trans-
fecting the human, EGFR-negative small-cell lung cancer cell line,
GLC3, with EGFRvIII in a Tet-On system. The transfected cells
were found to be more invasive in vitro and to have a lower
number of junctional complexes as compared to the vector
controls.1 Cell lines were cultured at 37˚C in humidified 5% CO2
in RPMI 1640 medium (Life Technologies, Scotland) supple-
mented with 10% heat-inactivated tet-approved fetal calf serum
(Clontech, UK). EGFRvIII expression in the transfected cells was
induced by addition of 2 µ gm l –1 doxycycline. The control cells
were treated simultaneously with the same concentration of doxy-
cycline. 
Biotinylated probes preparation 
Total RNA was isolated from 108 cells using Trizol reagent (Life
Technologies, UK). 10 µ g of total RNA pooled from 4 indepen-
dent samples was used as starting material for cDNA preparation.
Double-stranded cDNA was prepared using Life Technologies
(UK) Superscript Choice system™ according to manufacturer’s
instructions using an oligo(dT)24-anchored T7 primer. Biotinylated
RNA was synthesized using the T7 MEGAscript in vitro transcrip-
tion kit (Ambion Inc, TX, USA) with biotin-11-CTP and biotin 16-
UTP (Enzo, NY, USA) for 4 h at 37˚C. In vitro transcription
products were purified using RNeasy columns from Qiagen (UK). 
Array Hybridization and Scanning 
10 µ g of the biotinylated RNA was fragmented for 35 min at 94˚C
in a buffer composed of 40 nM Tris-acetate, pH 8.1, 100 nM
KOAc, and 30 nM MgOAc. Prior to hybridisation, the fragmented
cRNA was heated to 95˚C for 5 min in a 6 × SSPE-T hybridisation
buffer (1 M NaCl, 10 mM Tris pH 7.6, 0.005% Triton) and subse-
quently at 40˚C for 5 min before loading onto the Affymetrix
probe array cartridge. The probe arrays were incubated for 16 h at
40˚C at constant rotation (60 rpm). Fluidic station 400 from
Affymetrix was used for washing and staining of the arrays. 
The probe array was washed 10 times in 6 × SSPE-T at 25˚C
followed by 4 washes in 0.5 × SSPE-T at 50˚C. A 3-step protocol
was used for detection of the hybridised biotinylated RNA: first the
probe array was incubated with a streptavidin- phycoerythrin conju-
gate, 10 µ gm l –1 (Molecular Probes, OR, USA) in 6 × SSPE-T for
30 min at 25˚C followed by labelling with an anti-streptavidin goat
biotinylated antibody (Vector Laboratories, Burlingham, CA,
USA) and a final staining again with the streptavidin-phyco-
erythrin conjugate. 
The Probe arrays were scanned at 560 nm using a confocal laser
scanner with an argon ion laser (Hewlett Packard GeneArray
Scanner G2500A). The digitalized image data were processed
using the Affymetrix Gene Expression Analysis Software (version
3.1). For comparison between chips, they were scaled to a global
intensity of 150, as previously published (Der et al, 1998;
Kaminski et al, 2000). 
Northern blot analysis 
15 µ g of total RNA isolated using Trizol reagent (Life
Technologies, Inc), was size fractionated on a 1% agarose-
formaldehyde gel in MOPS buffer and transferred to a MAGNA
nylon membrane (MSI). The integrity of the RNAs was assessed
by analysing the 18S and 28S ribosomal bands. 
The human thymosin beta-10, 4F2 heavy chain, CD36, ATF-3
and c-kit cDNA probes of 500 bp were generated by a reverse
transcription-polymerase chain reaction (RT-PCR). The primers
were designed according to the published sequences. The probes
were labelled with [α -32P] CTP using the multiprime DNA
labelling system RPN.1601 (Amersham Pharmacia Biotech).
Membranes were hybridised with the probes in ExpressHyb™
hybridisation solution (Clontech, CA, USA) according to manu-
facturer’s directions. The membranes were exposed to Kodak X-
ray film with an intensifying screen at  80˚C for autoradiography.
The 18S and 28S bands were visualized on the blots by UV illumi-
nation and the 18S used for normalization of RNA loading. The
autoradiograms were analysed by the Kodak Digital Science soft-
ware and changes in expression calculated on the basis of relative
band intensities. 
Western blot analysis 
Cells were lysed in 20 nM Tris-acetate, pH 7.0, 0.27 M sucrose,
1 mM EDTA, 1 mM EGTA, 50 nM NaF, 1% Triton X-100, 5 mM
Na-pyrophosphate, 10 mM Na-beta-glycerophosphate, 1 mM
sodium orthovanadate, 10 µ gm l –1 aprotinin, and 10 µ gm l –1
PMSF. 5 µ g of protein lysate was resolved by SDS-PAGE on
2–8% gradient gels (Invitrogen, the Nederlands). Proteins were
transferred to PVDF membranes (Invitrogen, the Nederlands) and
incubated in 5% non-fat dry milk in 10 mM Tris pH 7.5, 100 mM
NaCl, 0.1% Tween for 1 h. Immunoblotting of primary antibody
was performed in the same buffer overnight at 4˚C. Filters were
extensively washed in 10 mM Tris pH 7.5, 100 mM NaCl, 0.1%
Tween and bound antibodies were detected by incubation with
alkaline-phosphatase conjugated secondary antibodies at 1:1000
for 1 h followed by washing and staining with a NBT/BCIP solu-
tion (Roche, Switzerland). 
RESULTS 
Gene expression profile of cell lines 
RNA was isolated from the small-cell lung cancer cell line trans-
fected with EGFRvIII (induced with doxycycline for 24 h or 48 h)
or a vector control cell line (uninduced or induced with doxycy-
cline for 48 h). The amplified, biotinylated RNA was hybridised
to Affymetrix GeneChips, which were subsequently stained,
1Epidermal Growth Factor Receptor Mutation Type III Transfected Into a Small Cell
Lung Cancer Cell Line Is Predominantly Localized at the Cell Surface and Enhance
the Malignant Phenotype. Damstrup L, Pedersen MW, Bastholm L, Elling F, Poulsen
HS (submitted).scanned, and analysed using the GENECHIP 3.1 software. The
intensities for gene transcripts (average differences) detected as
present (P) represented a range spanning 3 orders of magnitude,
from approximately 20 to the highest recorded value of 10 006 for
ribosomal protein S2 (data not shown). However, the majority of
the mRNAs detected had intensities of less than 1000. The genes
associated with intensities greater than 1000 (≈ 400) include many
of the ribosomal genes and commonly known high abundance
genes such as tubulin, elongation factor 2 and ubiquitin.
Interestingly, a number of cancer-related genes also had intensities
above 1000 including: V-myc avian myelocytomatosis viral onco-
gene homologue, human pancreatic tumour-related protein, human
tumour-associated 120 kDa nuclear protein (p120), and tumour
protein, translationally controlled 1. Their high expression in the
GLC3 cell lines suggests that they might play a role in the devel-
opment of small-cell lung cancer. 
To identify genes regulated by EGFRvIII a comparison was gener-
ated between the data sets from the GLC3-EGFRvIII induced with
doxycycline for 24 h or 48 h and the vector control either uninduced
or induced with doxycycline for 48 h. The level of gene expression of
control cells after 48 h of doxycycline induction did not change. 
Approximately 800 genes were identified whose mRNA expres-
sion levels were changed in the EGFRvIII expressing cells as
compared to the control stimulated for 48 h with doxycycline. The
majority of these (> 80%) represented genes for which the degree of
change was less than 2-fold. 225 genes had a fold change (ratio of
average differences) of 2 or more and had average difference
changes (the difference between the EGFRvIII expressing cells and
the control average differences) of more than 50 in either of the two
time points as compared to the control. 188 genes had altered
expression upon induction of EGFRvIII expression for 24 h and 175
after 48 h of induction as compared to the control. The majority of
these 150 have similar expression at the two time points. 
These genes were crudely divided into 13 categories on the
basis of the cellular function of the protein they encode (transcrip-
tional regulation, cytoskeletal and adhesion, metabolic, receptors
and ligands, cell cycle, signal transduction, ribosomal, nuclear,
translational regulation, apoptosis, immune-related, cancer-
related, and miscellaneous). Due to space limitations only 9 of the
categories are shown in Table 1. 
It was not possible to detect EGFRvIII transcripts using the
probe set for the EGFR precursor (X00588). The EGFR precursor
mRNA extends 1701 bases longer in the 3′ end compared to the
processed EGFRvIII mRNA. The 20 probes for detection of the
EGFR precursor on the chip are designed to hybridise to sequences
in this area and therefore cannot recognize EGFRvIII mRNA. 
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Table 1 List of genes whose expression changed more than 2-fold between EGFRvIII- and control cells sorted on the basis of their cellular function:
Transcriptional regulation (A), cytoskeletal or adhesion (B), receptors and ligands (C), cell cycle (D), apoptosis (E), signal transduction (F), and cancer related
(G). The first 2 columns show the fold change in the gene expression between the vector controls and the doxycycline-induced (24 h or 48 h) EGFRvIII-
expressing cells. At the bottom of each panel is an explanation of the colour codes used. The third and fourth columns describe the genes expressed and their
Genbank accession. The absolute call states whether the gene transcripts are present (P), marginally present (M) or absent (A) in the experimental file.
Difference call is a call of the change either decreased (D), increased (I), no change in (NC), marginally decreased (MD), or marginally increased expression
(MI) of a particular gene. Average difference change (Avg. Diff. Change) is a measure of the change of intensities in expression of a particular gene 
A
Fold Change GenBank
24th. 48th.
Transcriptional Regulation
Description Absolute Call
24th. 48th. 24th. 48th. 24th. 48th.
Diff.Call Avg.Diff.Change
- 16.0 - 16.0
- 12.7 - 12.7
- 6.4 - 3.7
- 4.1 - 4.1
- 3.8
- 2.9 - 2.5
- 2.7 - 2.7
- 2.6
- 2.4 - 2.4
- 2.3 - 2.3
- 2.2 - 2.2
- 2.2 - 2.2
- 2.1
- 2.0
- 2.0
- 2.4
- 2.0
- 2.1
- 2.0 - 2.0
- 2.0
- 2.1
- 2.0
- 2.4
- 3.1 - 2.6
- 4.8 - 4.6
- 4.9 - 3.1
- 8.1 - 5.6
>5 <2 >-2 <-2 <-3 -<5 >3 >2
Fold Induction Fold Repression
U22376
L37868
M93119
X82125
L23959
M88163
X52611
M16937
U80017
Z11933
D85425
X70683
U07559
HG3566
U32849
JO5249
AF005887
X56681
M77698
U96915
M31627
U49857
U35048
HG2724
L198871
c-myb gene extracted from Human (c-myb) “gene” complete primary “cds,”
“Homo sapiens POU-domain transcription factor ““(N-Oct-3),”” complete cds”
Human zinc-finger DNA-binding motifs (IA-1) “mRNA,”complete cds
H. sapiens HOK-2 mRNA for zinc finger protein
Homo sapiens E2F-related transcription factor (DP-1) “mRNA,” complete cds
Human global transcription activator homologous sequence “mRNA,” complete cds
Human mRNA for transcription factor AP-2
Human homeo box c1 “protein,” “mRNA,” complete cds
Human basic transcription factor 2 p44 (btf2p44) gene, partial cds
“H.sapiens mRNA for N-Oct ““3,”” ““N-Oct5a,”” and N-Ocy 5b proteins”
“Human mRNA for transactivator ““HSM-1,””complete cds”
H.sapiens mRNA for SOX-4 protein
Human ISL-1 (Islet-1) “mRNA, “complete cds
Zinc Finger Protein (Gb:M88359)
Human Hou “mRNA,” compete cds
Human replication protein A 32-kDa subunit “mRNA,: complete cds
Homo sapiens ATF family  membe ATF6 (ATF6) “mRNA,”
Human junD mRNA
Homo sapiens GLI-Krupple related protein (YY1) “mRNA,” complete cds.
Homo sapiens sin 3 associated polypeptide p18 (SAP18) “mRNA, “complete cds.
Human X box binding protein-1 (XBP-1) “mRNA,’ comlpete cds
Human transcriptional activator “mRNA,: complete cds
Human TSC-22 protein “mRNA” complete cds
Oncogene “Tis/Chop, “Fusion Acticvated
Human activating transcription factor 3 (ATF3) “mRNA,” complete cds
P
M
A
A
A
A
A
A
A
A
P
P
A
A
P
P
A
P
P
P
P
A
P
P
P
P
M
P
A
P
P
A
P
A
A
P
P
P
M
P
P
P
P
P
P
P
P
P
P
P
D
D
D
D
D
D
D
D
D
D
D
D
D
NC
NC
I
NC
I
I
MI
I
NC
I
I
NC
D
D
D
D
NC
D
D
NC
D
D
D
D
NC
D
I
I
NC
I
I
MI
I
MI
I
I
I
-157
-123
-138
-128
-79
-55
-127
-55
-59
-62
99
-722
-71
-9
43
218
67
1098
234
184
331
74
491
1360
202
-157
-123
-88
-128
25
-50
-127
-15
-59
-62
-99
-722
-51
-153
73
316
41
1098
229
184
207
55
468
756
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>5 <2 <-2 <-3 <-5 >3 >2
Fold Induction Fold Repression
P
A
P
A
A
P
A
P
A
P
P
A
P
A
A
A
P
A
P
P
P
P
P
P
P
P
A
P
A
A
P
P
P
A
P
P
P
P
A
A
P
P
P
P
P
P
P
P
P
P
D
D
D
D
NC
D
D
D
D
D
D
NC
NC
D
D
D
D
NC
I
I
I
I
I
I
I
-161
-156
-250
-153
-84
-615
-348
-416
-73
-140
-568
-101
-196
-53
-146
-94
-407
-60
57
126
135
640
230
56
79
-161
-571
-250
-153
-36
-615
-320
-310
-73
-140
-568
-61
-121
-53
-146
-81
-407
-64
120
129
135
640
283
74
85
Fold Change GenBank
24th. 48th.
Cytoskeletal or Adhesion
Description Absolute Call
24th. 48th. 24th. 48th. 24th.48th.
Diff.Call Avg.Diff.Change
B
- 4.7 - 4.7
- 4.0
- 3.0 - 3.0
- 3.0 - 2.6
- 2.9
- 2.8 - 2.8
- 2.7 - 2.7
- 2.5 - 2.5
- 2.4
- 2.4
- 2.3
- 2.3
- 2.3
- 2.5
- 2.4
- 2.3 - 2.1
- 2.2
- 2.2
- 2.3
- 2.5 - 2.5
- 3.1 - 3.5
- 3.2 - 4.7
- 3.8 - 2.8
- 2.0
- 2.3
- 2.3
- 2.3
- 2.2
- 2.3
>-2
M98399
AB000114
L33930
X698819
D14678
Z24727
U03057
M82809
X05608
U46006
M19267
M61916
L33477
X54304
X98801
M55210
Z32765
HG2442
L19783
L04733
X06956
J04029
U20582
U21128
D21255
“Human antigen CD36 (clone 21) “mRNA,” complete cds”
Human mRNA for “osteomodulin,” complete cds
“Homo sapiens CD24 signal transducer “mRNA,”
H.sapiens ICAM-3 mRNA
Human mRNA for kinesin-related “protein,” partial cds
H.sapiens tropomyosin isoform “mRNA,” complete CDS
Human actin bundling protein (HSN) “mRNA,” complete cds
Human annexin IV (ANX4) “mRNA,” complete cds
Human gene for neurofilament subunit NF-L
“Human smooth muscle LIM protein (h-SmLIM) “mRNA,”
“Human tropomyosin ““mRNA,” complete cds”
Human laminin B1 chain “mRNA,” complete cds
Human (clone 8B1) Br-cadherin “mRNA complete cds
Human mRNA for myosin regulatory light chain
H.sapiens mRNA for dynactin
Human laminin B2 chain (LAMB) gene
H.sapiens CD36 gene exon 15/gb=Z32765/ntype=DNA/annot=exon
Tropomyosin, “Alpha,” “Muscle,” Alt. Splice “2,” Skeletal Muscle (Fibroblast)
Human GPI-H “mRNA,” complete cds
Homo sapiens kinesin light chain “mRNA,” complete cds
Homo HALPA44 gene for ““alpha-tubulin,””exons 3-Jan”
“Homo sapiens keratin 10 type I intermediate filament (KRT10) ““mRNA
“Human actin-like peptide “mRNA, “partial cds
Human lumican “mRNA,” comlete cds
Human mRNA for “OB-cadherin-2,”complete cds
D
NC
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
NC
NC
I
I
NC
MI
I
- 16.3 - 16.3
- 6.5 - 12.9
- 5.8 - 5.8
P
A
P
A
P
A
P
P
A
P
P
P
A
P
A
P
A
P
P
P
P
P
D
NC
D
D
D
D
D
I
I
MI
MI
-543
-67
-126
-57
-237
-48
-256
95
18
99
66
Fold Change GenBank
24th. 48th.
Receptors and Ligands
Description Absolute Call
24th. 48th. 24th. 48th. 24th.
Diff.Call Avg.Diff.Change
C
X06182
M21551
U19247
S77410
X98248
M60278
D13641
L38487
L10373
HG3415
J05200
D
D
D
D
D
NC
D
NC
NC
MI
MI
D
48th.
- 6.1 - 6.1
- 3.4
- 2.8 - 2.8
- 2.2 - 2.2
- 2.1 - 2.1
- 7.2
- 2.0
2.2
2.1
2.8
3.9
3.1
3.9
Human c-kit proto-oncogne mRNA
Human neuromedin B mRNA complete cds.
Human inferferon-gamma receptor alpha chain gene
“type1 angiotensin II receptor”“[human,”“liver,”“mRNA,”“2268 nt]”
H.sapiens mRNA for sortilin
Human heparin-binding EGF-like growth factor “mRNA,” complete cds
Human mRNA for KIAA0016 “gene,” complete cds
Human estrogen receptor-related protein (hERRa1) “mRNA,”3’ “end,”
Human (clone CCG-B7) mRNA sequence
Poliovirus Receptor
“Human ryanodine receptor ““mRNA,” complete cds”
-543
-22
-126
-57
-237
-123
-287
184
55
86
66
Fold Change GenBank
24th. 48th.
Cell Cycle
Description Absolute Call
24th. 48th. 24th. 48th. 24th.
Diff.Call Avg.Diff.Change
48th.
- 3.6 - 3.6
- 2.3 - 2.3
- 2.1 - 2.1
- 2.1
2.1 3.3
10.6 10.6
“Human butyrophilin (BTF4)” “mRNA,” “complete cds”
“Human butyrophilin (BTF4)” “mRNA,” “complete cds”
Human mRNA for cyclin A
Human Hs-cul-1 “mRNA,” comlete cds
Human thymidylate kinase (CDC8) “mRNA,” complete cds
G0S2 gene extracted from Human GOS2 “gene,” 5’ flank and cds
A
P
A
P
P
P
-115
-276
-125
-387
100
101
A
P
A
P
P
P
D
D
D
D
NC
MI
D
D
D
D
MI
MI
-115
-276
-125
-273
110
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As can be seen on Table 1 (A) the expression of many genes
encoding transcription factors were altered in the EGFRvIII trans-
fected cell line induced for both 24 and 48 h as compared to the
vector control induced for 48 h. These included the genes for c-
Myb, transcription factor AP-2, JunD, N-Oct 3, SOX-4, TSC-22
and activating transcription factor 3 (ATF-3). 
Changes in expression of genes encoding cell adhesion mole-
cules and structural proteins were also found (Table 1, B). For
example, the cell adhesion molecules CD36, CD24 and ICAM-3
were decreased at both time points, while increased expression
was observed for the gene encoding OB-cadherin-2. The expres-
sion of different growth factors and receptors were also altered. A
decrease in the level of mRNAs encoding the Kit receptor,
heparin-binding EGF-like growth factor, interferon-gamma
receptor alpha chain, were observed (Table 1, C). 
In the GLC3-EGFRvIII the level of only a few mRNAs
encoding signal transduction molecules was altered. Most impor-
tantly an increase in mRNA levels was found for MAP Kinase
Phosphatase 1 (MKP-1, CL100), (Table 1, F). 
Amongst the category of genes related to cancer the mRNA levels
of Mac-2 binding protein, Hsp70, MAGE-11 decreased at both time
points, while the level of mRNAs encoding 4F2 light chain (E16),
4F2 heavy chain, and collagenase 3 were increased (Table 1, G). 
Verification of selected results by Northern blot
analysis 
In order to confirm changes in mRNA levels detected by the
GeneChip analysis, Northern blot analyses were performed. 5 gene
products were selected: c-kit, CD36, and thymosin beta 10 whose
expression were decreased and 4F2 glycosylated heavy chain and
ATF-3 whose expression were increased. 
As can be seen in Figure 1A the c-kit mRNA level decreased in
EGFRvIII transfected cell line by a factor of 6.8 (24 h) and 7.4 
(48 h) as calculated by the band intensities on the Northern blot
(6.1 and 6.1 by GeneChip analysis) respectively in the GLC3-
EGFRvIII doxycycline-induced cells as compared to the control
cells doxycycline induced for 48 hours. 
The fold change in CD36 expression in Northern blot could not be
calculated as no CD36 mRNA could be detected in the EGFRvIII-
transfected cell line doxycycline induced for 24 or 48 h. The level of
thymosin beta 10 was decreased by a factor of 6.3 and 10 (2.6 and
>5 <2 <-2 <-3 <-5 >3 >2
Fold Induction Fold Repression
A
A
A
P
A
P
P
P
P
A
P
A
P
P
A
P
P
P
P
P
-80
-174
-145
-351
-216
-113
80
144
55
142
Fold Change GenBank
24th. 48th.
Signal Transduction
Description Absolute Call
24th. 48th. 24th. 48th. 24th.
Diff.Call Avg.Diff.Change
F
>-2
M31158
X60673
M15205
U09564
X89416
M86699
S74221
U07563
X68277
U27655
D
D
D
D
D
NC
NC
NC
I
NC
G
48th.
-72
-174
-36
-314
-216
-126
99
122
55
108
L13210
M11717
U17714
U10686
L02785
M80244
M21904
X75308
Fold Change GenBank
Cancer Related
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Figure 1 Northern blot analyses (A) and corresponding hybridisation GeneChip results (B) of 5 selected genes that were differentially expressed in the GLC3-
EGFRvIII cell line as compared to the vector control. The autoradiograms (middle) show the mRNA levels of c-kit, Thymosin Beta-10, CD36, 4F2 heavy chain
and ATF-3 in the 4 cell samples. The first panel for each molecule shows a comparison between fold change measured by GeneChip (black) and net intensity of
the bands generated by Northern blot analysis (red). The lower panels show the 18 S ribosomal bands visualised on the blots by UV light and were used as
mRNA loading controls. Shown in panel B are the corresponding GeneChip hybridisation results, where white/red designates a high level of hybridisation while
blue/black indicates a low level of hybridisation. The first row is the perfect match hybridisation and the second row the hybridisation to the corresponding
mismatch oligonucleotide probes, used as subtraction for unspecific hybridisation 
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2.6 by GeneChip analysis) in the GLC3-EGFRvIII cell line as
compared to the control cell line. The 4F2 heavy chain mRNA was
increased by a factor of 3.1 and 2.7 (3.5 and 3.0 by GeneChip
analysis) respectively in the GLC3-EGFRvIII doxycycline-induced
cell as compared to the control cell doxycycline induced for 48 h.
Finally the level of 
ATF-3 increased by factors of 7.5 and 7.6 (8.1 and 5.6 by
GeneChip analysis). 
Verification of results by Western blot analysis 
We performed Western blot analysis on 3 selected proteins in order
to further validate our GeneChip data. CD98 (4F2 heavy chain and
4F2 light chain) and MKP-1 were chosen, as specific antibodies
were commercially available. 
A significant increase in the protein level of MKP-1 was
observed, as seen in Figure 2A, in the EGFRvIII transfected cells
when compared to the control cells. MKP-1 was barely detectable
in the control cell line both uninduced and doxycycline-induced.
Under the conditions of the Western blot analysis the CD98 dimer
separates as a heavy chain and a light chain, 4F2HC and 4F2LC
respectively which both are detected by the CD98 antibody.
Shown in Figure 2B are the results from the Western blot analysis
of CD98. The level of both 4F2LC and 4F2HC increased, although
more pronounced for the latter, when comparing the EGFRvIII-
expressing cells with the control cells. 
DISCUSSION 
The role of the constitutively active EGFRvIII in the development
and progression of cancers has been studied extensively over
the past several years, and the ability of EGFRvIII to transform
fibroblasts in vitro and confer enhanced tumorigenicity to cancer
cells both in vitro and in vivo are supported by numerous studies
(Garcia et al, 1993). However, little is known about the molecular
mechanisms behind this ability of EGFRvIII, although EGFRvIII
clearly induces a signal transduction network distinct from that of
the ligand-activated EGFR (Antonyak et al, 1998; Moscatello et al,
1998; Lorimer and Lavictoire, 2001). Virtually nothing is known
about genes whose expression is regulated by EGFRvIII. Thus to
identify novel EGFRvIII-regulated genes, oligonucleotide arrays
were used to study the changes in mRNA levels induced by
expression of EGFRvIII in the GLC3-EGFRvIII cell line
compared to a vector control. The use of oligonucleotide arrays
allows simultaneous analysis of expression profiles of thousands
of genes. To our knowledge this is the first comprehensive study of
transcriptional changes related to EGFRvIII. 
We identified 225 genes whose expression was up-or down-
regulated by at least a factor of 2 in either of the two time points of
induction used and the majority of these had similar expression at
the two time points. The similarity of the expression results at the
two time points correlate well with the constitutive nature of the
EGFRvIII. The addition of doxycycline did not influence the level
of gene expression in the control cells. A few of the results from
the gene chip analysis were verified by Northern blot analysis and
we found a strong qualitative correlation between oligonucleotide
array hybridisation data and Northern blot analysis (Figure 1).
Furthermore, to test the strength of the gene chip analysis, genes
were selected that had increased expression (4F2 heavy chain and
ATF-3) or decreased expression (c-kit, CD36 and thymosin beta
10) and either high level of expression (4F2 heavy chain, thymosin
beta 10) or low level of expression (CD36 and ATF-3). For
completeness a correlation between array expression results and
changes in protein levels were confirmed for 4F2 heavy chain, 4F2
light chain and MKP-1. 
Many of the differences in expression level between the
EGFRvIII-expressing cell line and the control cell line makes
sense. For example MKP-1 (CL100) has been proposed to mediate
the cross talk between the constitutively active JNK signal trans-
duction pathway and the Ras/Raf/ERK signal transduction
pathway at the level of ERK, resulting in inactivation of the latter
in EGFRvIII-transfected cells (Antonyak et al, 1998). We found an
increased level of MKP-1 mRNA and protein in our EGFRvIII-
expressing cells after induction of EGFRvIII expression thus
supporting this hypothesis. In addition we found an increased
expression of a number of other genes that are known to be 
Figure 2 5 µ g aliquots of whole-cell lysates were processed for Western
blot analysis. MKP-1 levels (A) were detected using rabbit polyclonal
antibodies directed against MKP-1. The level of MKP-1 was only detectable
in the GLC3-EGFRvIII cell line. CD98 (4F2 heavy and light chain) levels (B)
were detected using rabbit polyclonal antibodies directed against CD98. The
level of CD98 was higher in the EGFRvIII transfected cell line as compared
to the vector controls. The amount of protein loaded being similar was in all
cases verified using mouse monoclonal antibodies directed against human
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regulated by active JNK which include ATF-3, collagenase 3
(MMP-13), and Jun D. Again this supports the finding from other
EGFRvIII transfected cell lines that EGFRvIII utilises a constitu-
tively active PI3K/JNK pathway (Antonyak et al, 1998;
Moscatello et al, 1998). 
We have previously found that the EGFRvIII-transfected GLC3
cell line had an increased invasive capacity in vitro as compared to
the vector control. Interestingly the mRNA level of collagenase 3
was increased in these cells as compared to the vector control.
Collagenase 3 expression has been documented in various cancers
which are aggressive and invasive. In particular collagenase 3
expression was seen at the invading front (Brinckerhoff et al,
2000). Collagenase 3 therefore seems to play an important role in
tumour invasion and one could speculate that there might be a
correlation between the collagenase expression in the EGFRvIII-
transfected cell line and their invasive potential. We are currently
testing this hypothesis. 
Our data demonstrate that amongst the 6800 human genes
examined, the expression of 225 were altered more than 2-fold in
either of two time points after induction of EGFRvIII expression.
All of these represent potential EGFRvIII-regulated genes not
previously described and include a number of genes encoding
transcription factors, cell adhesion molecules, and other genes
related to cancer. However, a significant portion of the genes have
at present no known function. Our comprehensive data may prove
useful in the future as many, or all, of these genes will be charac-
terized. This will give further insight into the role of EGFRvIII in
the malignant phenotype. We did not compare the changes in the
EGFRvIII-transfected cell line with a EGFR-transfected SCLC
cell line. This was not performed as EGFR-transfected cells 
were not available but most importantly, it was not clear which
time point after EGF addition would be relevant to use for compar-
ison. Furthermore, such a comparison would most likely have
limited value as differences in the pathways used between EGFR
and EGFRvIII are clearly described (Antonyak et al, 1998;
Moscatello et al, 1998; Lorimer and Lavictoire, 2001). We are
currently evaluating results in other EGFRvIII-expressing cell
lines and in xenotransplanted tumours to clarify whether the
results described herein are receptor or cell-type specific. 
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